States expect higher Medicaid enrollment in 2021 | Dems question Trump's authority to order $200 Medicare drug cards | Ga. to drop health insurance exchange
October 16, 2020
PCMA SmartBrief
News for the PBM IndustrySIGN UP ⋅   SHARE ⋅   ARCHIVE
Featured Story
A Kaiser Family Foundation survey of state Medicaid directors found that total Medicaid spending climbed by 6.3% in fiscal year 2020 despite relatively flat growth in Medicaid enrollment. For fiscal year 2021, Medicaid directors expect an 8.4% jump in total Medicaid spending and 8.2% increase in Medicaid enrollment amid the economic downturn fueled by the COVID-19 pandemic and new maintenance of eligibility rules.
Full Story: FierceHealthcare (10/15) 
LinkedIn Twitter Facebook Email
Legislative & Regulatory News
Democratic lawmakers say President Donald Trump does not have the authority to spend billions of dollars allocated to Medicare on $200 prescription copay cards, making it unlikely the cards will be mailed before Nov. 3.
Full Story: The Associated Press (10/16) 
LinkedIn Twitter Facebook Email
The CMS approved Georgia Gov. Brian Kemp's request to disconnect the state from and, instead of setting up a state-run health insurance exchange, offer federally subsidized health plans through agents, brokers, and health insurers. The Trump administration also approved Georgia's proposal to require work, volunteering, job training, or school attendance of able-bodied adults on Medicaid, and to impose monthly premiums.
Full Story: The Associated Press (10/15) 
LinkedIn Twitter Facebook Email
Senate Majority Leader Mitch McConnell, R-Ky., rejected the prospect of a pandemic relief package worth between $1.8 trillion and $2.2 trillion, saying Senate Republicans "think half a trillion dollars, highly targeted, is the best way to go." McConnell made the comment after President Donald Trump indicated willingness to increase his current $1.8 trillion offer for the next relief bill as talks continue between the White House and Democrats.
Full Story: The Hill (10/15) 
LinkedIn Twitter Facebook Email
Drug Industry Spotlight
Gilead's remdesivir did not appear to prevent the death of hospitalized COVID-19 patients in a study involving more than 11,300 adult patients in 405 hospitals in 30 countries. However, different treatment protocols in different countries might have affected the outcome, says infectious disease expert Peter Chin-Hong.
Full Story: The New York Times (tiered subscription model) (10/15) 
LinkedIn Twitter Facebook Email
Why pausing COVID-19 trials is reassuring
(Mladen Antonov/AFP/Getty Images)
Experts said pauses in COVID-19 vaccine or treatment clinical trials by Johnson & Johnson, Eli Lilly and Co. and AstraZeneca because of safety concerns should be reassuring because they show the companies are following proper safety procedures.
Full Story: The Hill (10/14),  The New York Times (tiered subscription model) (10/14) 
LinkedIn Twitter Facebook Email
Acceptance is going to a restaurant where the salad's not great, but the steak is fine.
Albert Brooks,
actor, comedian, writer, director
LinkedIn Twitter Facebook Email
Upcoming PCMA Events  |    PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004